B
BioVersys
Biotech & Life Sciences · Basel, Switzerland · Founded 2010
Privately held Swiss biopharmaceutical company MoreLess
BioVersys is a Swiss pharmaceutical company based in Basel, specializing in the research and development of small molecules targeting antimicrobial resistance (AMR). The company focuses on creating therapies that address bacterial infections through novel modes of action and targets. BioVersys operates in the pharmaceutical and biotech sectors, serving healthcare systems globally by providing solutions to combat the silent pandemic of AMR. The business model revolves around advancing clinical trials and bringing effective treatments to market, thereby generating revenue through the commercialization of its pharmaceutical products. The company is governed by a board of directors with extensive experience in the pharma and biotech industries, ensuring strategic oversight and guidance. BioVersys is committed to improving patient outcomes and safeguarding global health by addressing one of the most pressing medical threats of our time. Keywords: antimicrobial resistance, small molecules, bacterial infections, pharmaceutical, biotech, clinical trials, healthcare, global health, therapies, Basel
Company overview
BioVersys company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2010
- Headquarters
- Basel, Switzerland
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 92.3
Valuation & funding
BioVersys funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Nov 2025 | $16M | — | Undisclosed | ↗ |
| IPOOther financing | Feb 2025 | $73M | $195M | Undisclosed | ↗ |
| LATE VCOther financing | Sep 2024 | $6M | $125M | Guangzhou Industrial Investment Fund | ↗ |
| SERIES COther financing | May 2024 | $14M | $125M | GSK | ↗ |
| SERIES COther financing | Jan 2023 | $10M | $125M | AMR Action Fund | ↗ |
| SERIES COther financing | Jul 2022 | Undisclosed | ↗ | ||
| GRANTOther financing | Jun 2021 | CARB-X | — | ||
| DEBTDebt | Apr 2021 | European Investment Bank | — | ||
| SERIES BOther financing | Sep 2020 | Business Angels Switzerland | — | ||
| GRANTOther financing | Oct 2019 | CARB-X | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $3.2M | +7.1% | −$29M | -919.4% |
| 2025 | $3M | +172.3% | −$18M | -601.9% |
| 2024 | $1.1M | -77.5% | −$17M | -1508.3% |
| 2023 | $4.9M | 0% | — | — |
| 2022 | $4.9M | 0% | — | — |
| 2021 | $4.9M | 0% | — | — |
| 2020 | $4.9M | — | — | — |
Growth signals
BioVersys website traffic
Latest recorded traffic for BioVersys is 4.1K monthly website visits, up 7.9% over the last three months. BioVersys's team grew 28.1% over the past year.
Hiring
Open positions at BioVersys
Current openings linked to this company in Dealroom.
Comparisons
BioVersys compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
BioVersys's talent
Source: Dealroom Talent Intelligence.
Investors
11 investors on BioVersys's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where BioVersys has talent and traffic
team presence
In the news
Latest news about BioVersys
Recent press, funding announcements, and product moves mentioning BioVersys — open to read from the original sources.
Market sentiment
What the market is saying about BioVersys
An AI-synthesized read of the highest-engagement posts about BioVersys on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioVersys’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.